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Previous studies have de monstrated that retinoids 
possess antineoplastic properties against melanoma. The 
purpose of this s tudy was to determine whether topically 
a pplied retinoic acid could prevent melanoma develop-
ment in syngeneic mice afte r intracutaneous cell inno-
culation. Trans-retinoic acid in DMSO was applied daily 
for 28 days after m elanoma implantation and tumor 
g rowth was qua ntitated by the uptake of [uC]thiouracil, 
a tracer compound specific for mela noma which is in-
corporated linearly according to the weight of the tu-
mor. Marked r eduction in tumor growth was noted at 
t he highes t concentration (0.1 %) tested and lesser but 
significantly decreased tumor growth patterns were also 
realized at lower concentrations in a dose-dependent 
manner. Thus, topically applied retinoic acid is capa ble 
o f inhibiting 891 me lanoma growth in vivo. 
The ant ineoplastic effects of retinoids have been demonstra-
ted both in vit ro [l - 5) and in vivo (6-8). Ant imelanoma prop-
erties, in particula r, have been noted in diverse experimental 
systems [3,.5,9- 11) . One controversia l aspect of these studies is 
whether retinoids are capable of inhibiting the growt h of estab-
lished, t ransplantable tumors [9). Felix et al (10] noted that 
h igh doses of vitamin A give n i.p. or orally had an inhibito ry 
effect on t he growth of S91 murine melanoma cells implanted 
s.c. in allogeneic mice while no such effect was noted in syn-
geneic animals (1 2). suggesting that the host's immune response 
was necessary fo r t he ant ineoplastic effects. In vit ro retinoid 
effects on tumor cells in t he absence of immunologic factors 
strongly suggest that other mechanisms are operative [9]. 
One reason for t he va riable results in t he in vivo studies may 
be the relative insensitivi ty of the methods by which tumor 
growth is quant itated. We have developed a sensit ive measure 
of melanoma growth which is an accurate and reproducible 
measure of melanoma mass. Previously it has been noted that 
t hiouracil (TU) is a fa lse precurso r of melanin synthes is and is 
selectively incorporated into actively melani zing cells 
[12-14). In the present study (1'1C]TU uptake in melan oma is 
used to quant itate tumor growt h. 
In order to investigate the ant itumor effects of topica lly 
a pplied retinoids, an animal model system of int racutaneous 
t umors has been developed whereby tumor cells are inoculated 
into upper dermal blister cav it ies created by negative suction 
p ressure. Unt reated, virtually 100% of these tumors will grow 
into palpable masses within 10 days [1.5 ]. The advantages of 
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t his system are: (1 ) t he tumors are located in an area of t he 
skin which close ly approximates human cutaneous melanomas, 
particularly melanoma metastases, and (2) topically applied 
retinoic ac id (RA) can be ut ilized, which avoids the toxicity 
fo und in virtually all systemic chemotherapeut ic models. Using 
this experimental system the effects of topically applied {3-
t rans-RA on recent ly implanted S91 melanomas were examined 
in mice. 
MAT ERIALS AND METHODS 
A nimal:; 
DBA/2 mice (Jackso n Labs, Bar Ha rbor, Maine) were housed in 
mesh cages, 5 animals per cage, wit h a constant supply of standard rat 
chow a nd wate r. Experimenta l and con t rol a nimals were selected at 
random and housed in separate cages. 
Reagents 
T he fo llowing mate rials were obta ined from New E ngland N uclear, 
Boston, Massachusetts: [1'C]TU (sp act 8.98 mCi/ mmol), P rotosol, and 
Econofluor. The following chemicals were obtained from Sigma Chem -
ical, St. Louis, Missouri : dimethyl sul fox ide (DMSO), 1)-trans-RA. A 
0. 1% concent ration of RA was made in DMSO and 0.1-ml a liquots 
were stored in a luminu m fo il -wrapped plastic vials at. -70"C un t il t he 
hour of use. Puri ty of RA was checked on high-performance liquid 
chromatography (HP LC) assay [16]. ["C]TU was dissolved in l M T ris 
buffe r, p h 8.0, a nd stored at 4 ·c. 
T umor Growth Assessment 
In order to determine whether a linea r relationsh ip ex ists between 
melanoma size and T U uptake, the following experiments were per-
fo rmed using f14C]TU. Flas ks we re seeded with varying numbers of S91 
mela noma cells. One day later, 5 J..LC i of I 1·'C]TU was incubated wit h 
the mela noma cells fo r 24 h. T he cells we re then ex ha ustive ly washed 
with serum-free F- 10 media (Gibco, Grand Island, New York ) unti l no 
radioactivity was noted in the eluate. T he ce lls were removed from t he 
plates wi t h 0.2 % edetic ac id, coun ted in a hemocytometer, and solubi -
lized in Protoso l. T he liquid scin t illan t. , Econofi uar was added and the 
rad ioactivity in the cells was determined by liquid scin i illat.ion assay. 
An in vivo corre late was perfo rmed by a llowing int racuta neously 
implanted S9l melanomas to metastasize to t he lungs. Twe nty-four 
hours before sacrifice ]14C]TU (5 pCi) was given i.p. After sacrifice, 
metastatic foci of varying sizes were excised a nd dried overnight in a 
55"C oven. T he t issues were then weighed, solubilized in P rotosol, and 
assayed fo r radioactivity by liquid scin t illa tion assay. 
Each of t he tumor sites of both RA-treated and DMSO-treated 
animals was assayed for ]1'C]TU uptake by a method identicalt.o t hat 
used for the metastatic foci described above. T he [14C]TU was given 
on the 28th day of t reatment , one day before sacrifice. 
Cell Culture 
A subclone of Cloudmen S91 murine mela noma cells has been 
mainta ined cont inuously for the past 3 years by growth in synge neic 
DBA/2 mice and subsequent cult ivation of tumor cells in 75-cm2 plastic 
Jl asks with 25 ml of nut rient mixture F- 10, heat inactivated 2% feta l 
calf serum, 10% horse serum , 10 mg/ml of streptomycin, and 100 U/ 
ml of penicillin G. The media were replaced every 3- 4 days and 
subcul tures were carried out weekly usi ng 0.2 % edetic acid ]15]. Cells 
for in vivo impla ntation were a lways taken from one of t he fi rst two in 
vit ro subcul ture passages. 
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Tumor lmplontation 
DBA /2 male brown, 20 to 2fi-g mice were used since they are 
syngeneic to S9 1 melanoma. The an imals were anesthetized with a 
combination of droperdol and fentanyl citrate (lnnova r, Pittman -
Moo re) given s.c. The hair of the ve ntral abdomen was removed with 
an electric clipper foll owed by app lication of a depilatory agent (Neet, 
Whit ehall ). A Dermovac suction blister apparatus (Instrumentar ium, 
Helsinsk i) was applied and a nega tive pressure of 150- 1.75 mm Hg was 
mainta ined for 1.2 min by which time early vesicles were noted 
11 5- 171. The pressure was then increased to 0 mm Hg and the suction 
cup was removed. 
The animals were t.hen placed in t he supine position and 50,000 S9l 
melanoma ce ll s in 0.05 ml se rum -free medium were injected into the 
blister cav ity with a 30-gauge needle. The mice were held in this 
position for 5 min to a llow the ce lls to settle to the ll oo r of t he vesicle 
ll fi l. 
RA Treatment 
Starti ng on the day a fter tumor implantation and for t he succeeding 
27 days, the inoculation sites of one group of an im als were treated daily 
with the topical application of 10 1'1 or RA, 0.1% in DMSO, whi le a 
seco nd group was treated with 10 1'1 of the DMSO vehicle alone. After 
28 days of therapy, the an imals were sacrificed by C0 2 asphyxiation 
and the wmor sites were excised. Sma ll amounts of overlying normal 
epithelium' were included in t.he biopsy sa mples since the tumor could 
not be excised intact without this t issue. A pa ra llel experiment was 
performed whereb.v ~:roups of animal s were treated with one of several 
different co ncentrations of RA (0. 1%, 0.05%, 0.01%) for 28 days. As 
with the previous study, the animals were then sacrificed and the tumor 
sites were excised. An additional group of animals was treated for 28 
days wit.h either 0.1% RA or the DMSO control and the treatment sites 
were exci ed and exa mined by light microscopy. 
S tatistical Methods 
The medi an radioactive counts were computed for the RA-treated 
and DMSO -t.reated animals and t he significance of' differences in 
medians was computed using the Wilcoxon rank sum tesl. In the dose-
response stud y the significance of' differences in median radioactive 
counts among the 4 groups was compared using the Kruskai-Wallis 
test and comparisons between each pair of groups were determined 
using the Wilcoxon rank sum test. 
RESULTS 
Tumor Growt.h Assessment 
The experiments that examined the correlation between cell 
inoculation s ize of 891 melanoma cultures a nd ["C]TU uptake 
demonstrate a strong linear re la t ions hip (Fig 1). The in vivo 
study of l' ''C]TU inco rporat ion in 891 melanoma metastases 
shows a s imila rly s trong correlation between tumor weight and 
[' ''C]TU uptake (Fig 2). One can reasonably infer that tumor 
weight varies directly with ce ll number (tumor mass). Thus one 
can conc lude that [' ''C]TU uptake in tumors is a good quanti-
tative measure of overall me la nom a growth. 
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FH~ .1. Co rrelation between cell inoculation size of S91 melanoma 
and I"C ITU inco rporation afte r 24 h. y = 22.30, s lope= .0013, H.= 
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FIG 2. Correlation between tumor weight (mg) of lung metastases 
and l"C]TU incorporation 24 h after i.p. injection . y = 772.2, slope= 
610.1 , R = .98. 
F IG 3. S9 .1 melanoma tumor growth in DBA/2 mice after 28 days 
of treatment. Mouse A was treated with DMSO and has a 8-mm blue 
nodule with a central crust. Mouse B was treated with RA and has no 
evidence of tumor. 
591 Melanoma Growth with RA Treatment 
Two separate trials, each comparing topical RA 0.1 % to 
DMSO were performed. The data for these 2 experiments were 
pooled for the purposes of analysis. Clinically, only 1 of the 35 
RA-treated animals had a visible or palpable tumor at the end 
of t he treatment period. No evidence of tumor was noted in the 
remaining 34 mice (Fig 3). Tumors were visible and/or palpable 
in each of the 30 DM80-treated animals (Fig 3). In a separate 
experiment, light microscopic examination of sites treated for 
28 days with 0.1 % RA revealed no evidence of residual tumor 
whi le all control animals had melanomas (Fig 4). Several of the 
RA-treated mice had evidence of cutaneous inflammation (er-
ythema, crusting) at some point during therapy while this was 
not observed in the DM80-treated animals. 
When a comparison is made between [14C]TU uptake in the 
RA-treated mice and the DMSO-treated animals, there is sig-
nificantly less incorporation in the retinoid-treated mice (Table 
I) (Fig 5). Thus, one can conclude that topical RA causes a 
substantial decrease in melanoma growth at the s ite of appli-
cation of the compound. 
The dose-response experiment compared S91 mela noma 
growth with varying concentrations of RA (0.1 %, 0.5 %, 0.01 %) 
and with the DMSO vehicle. Although there was some varia-
bility in tumor growth within each treatment group, there was 
no clinical evidence of tumors in the high concentration group 
(0.1 %) whi le steadi ly increasing tumor sizes were noted as the 
RA concentration dropped (Fig 6) . 
A ug. 1985 
F IG 4. A, Histology of mela noma impla ntation site a fte r 28 days of 
topical RA . No tumor cells a re noted (X 80). B, Histology of mela noma 
impla ntation site a fte r 28 days of DMSO vehicle. Note t he melanocytic 
tumor in the dermis (x 80). 
T ABL E l. f" C}Th ioura.cil t t U) uptahe after retinoic acid (RA) 
t reatment 
Treatment 
RA 
DMSO 
44 (13- 894)"· 1' 
N = 44' 
277 (45-3910) 
N = 30 
a Median dpm per mg of t issue. Num bers in pa rent heses are t he 
range of va lues. 
b p < .0001. 
'N = number of animals t reated. 
As one can see in T ables II and III, a ll concent rations of RA 
used caused significant ly smaller melanomas to develop than 
in DMSO-treated animals. In addition, there was a stepwise 
decrease in [14C]TU uptake as the concentrat ion of RA in-
c reased, indicating a dose-response relationship between reti-
n oid concent ration and tumor growt h (Fig 7). 
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FIG 5. [~' C]TU incorporation a fte r topical 0.1% RA therapy in S91 
mela noma. 
FI G 6. S91 melanoma growth after RA t reatment at di ffere nt con-
centrations. Note t.he punctate dark papule on the a nima l after RA 
0.05 %, the larger papule afte r RA 0.01 %, and the ve ry large, eroded 
nodu le in the DMSO-t reated mouse. 
TABLE IT. Effect of retinoic acid (RAJ concentration on f HC]thiouraciL 
('t U) upta.he after RA treatment 
RA concentration 
0.1% 
0.05 % 
0.01% 
DMSO 
47 (20- 95)a 
N = 10" 
78 (16- 178) 
N = 12 
172 (83- 683) 
N = 12 
327 (81- 1641) 
N = 34 
a Median dpm per mg tissue. Numbers in parentheses a re the ranges 
of va lues. 
• N = number of a nima ls t reated. 
TABLE Ill. Significance of difference between retinoic acid (RA) 
treatment concentration on f 1'C/thiouracil (TU) uptahe in S.9! 
melanoma 
0.0 1% 0.05% 0. 1% 
DMSO .02 <.001 <.001 
0.01% .001 .001 
0.05% .086 
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FIC; 7. ["CJT U inco rporation aft.er treatme nt with varying concen -
trations of topical RA in S91 melanoma. 
DISCUSS TON 
Although t he data on retinoid effects in cancer are somewhat 
controversial, there is sufficient encouraging evidence to war-
rant further wo rk with retinoids on tumors in general and with 
melanoma in particular. An experimental animal model system 
has been developed to test the hypothesis that RA can inhibi t 
tumor growth in transplanted tumors. This system may have 
implications in human cancer trials for two reasons: (1) the 
tumors are implanted near t he dermal-epidermal junction, the 
site of human melanomas, and (2) the transdermal delivery 
system of chemotherapeutic agents is potentially far less toxic 
to the host while a ll owing for s igni1icant dermal concentrations 
of the medication [18] . 
Topically app lied {3-all -trans-RA has been demonstrated to 
inhibit 891 mela noma tumor growth in syngeneic mice. The 
effects were most dramatic with a moderately high concentra-
tion (0.1 %) where a lmost no tumors were noted clinically and 
histologically after 28 days of t reatment but were a lso seen at 
lower concentrations in a dose-dependent manner. 
A common method of determining antitumor e fJects of cancer 
age nts is to measure t he area of the tumor by calipers, etc . after 
treatment [19] . In tumors wi t h irregular or indistinct margins 
or in those with varyi ng dens it ies, t hese measurements may 
not be accurate. The method of quantifying tumor growth in 
t his study, ['~C]TU uptake, has been s hown to be a sensitive 
indication of cell number as well as tumor weight. Since th is 
compound is incorporated into actively melanizing ce lls it 
should be usefu l in othe r pigmented cell lines. It is possible 
that the metabolic activities o f pigmented cells (melanization) 
and the proliferative behavior may not be linked so that [' 4 C] 
TU uptake would not reflect actual tumor growth, but rather, 
tumor pigmenting behavior. The subclone of 891 melanoma 
chose n in t his study is a highly pigmented line where virtually 
a ll cells appear to be producing melanin in vitro. The linear 
relation of [' 1C]TU uptake and tumor mass confirms that 
pigmentation and proliferation are proceeding in direct propor-
tion in t his cell line. In tumors with variable melanizing poten-
tia l, this method would like ly underestimate tumor size a nd 
would be less use ful. 
Since a ll animals were sac rificed after the 28-day treatment 
period, the ultimate fate of t he tumors with respect to local 
growth as well as metastatic spread is unknown. However, in a 
preliminary study we have treated 5 animals with 0.1% RA 
daily for 28 days and have observed these mice for an additional 
28 days. At the end of the obse rvation period no clinical 
ev idence of tumor growth was noted in 4 of the 5 a nimals. This 
was confirmed by light and electron microscopy (unpublished 
data). 
The mechanism(s) of retinoid antitumor effects is unknown 
but severa l hypotheses have been advanced including steroid 
hormone-like effects involving membrane retinoid-binding pro-
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teins [20], membrane glycoprotein synthesis modifications 
[21], stimulatory effects on gap junction synthesis [22], orni-
thine decarboxylase synthesis inhibition [23] effects on onco-
genes (24), and immunomodulating effects [3]. 
It is possible t hat inf1ammatory mediators play a crucial role 
in the antitumor effects noted in t his study since most of the 
retinoid-treated animals had mode rate erythema with retinoid 
application. Preliminary electron microscopic studies from our 
laboratory (unpublished) s how on ly minimal dermal inflam-
matory cell s at the site of t umor implantation at any time 
during the 28-day course of t reatment. This casts doubt on the 
contention that nonspecific inf1ammation is responsible for 
tumor cell necrosis. 
The author wishes to thank Dr. Thomas Moon and Mr. Steven 
Rodney for statistical ana lysis of the data and Dr. David Alberts for 
performing the HPLC assays. 
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